Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $7.33.
A number of equities analysts have recently commented on the stock. Jefferies Financial Group started coverage on shares of Codexis in a report on Monday, June 3rd. They issued a “buy” rating and a $5.00 price target on the stock. Cantor Fitzgerald started coverage on shares of Codexis in a report on Thursday, May 30th. They set an “overweight” rating and a $11.00 target price on the stock. Finally, Benchmark reaffirmed a “buy” rating and set a $9.00 target price on shares of Codexis in a report on Friday, May 3rd.
Read Our Latest Analysis on CDXS
Institutional Trading of Codexis
Codexis Price Performance
Shares of NASDAQ:CDXS opened at $3.30 on Monday. The company’s fifty day moving average price is $3.25 and its 200-day moving average price is $3.22. The firm has a market capitalization of $232.85 million, a price-to-earnings ratio of -3.55 and a beta of 2.12. Codexis has a one year low of $1.45 and a one year high of $4.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.71 and a quick ratio of 3.63.
Codexis (NASDAQ:CDXS – Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. The firm had revenue of $17.07 million for the quarter, compared to analyst estimates of $14.06 million. Codexis had a negative net margin of 87.73% and a negative return on equity of 41.76%. On average, equities research analysts anticipate that Codexis will post -0.63 earnings per share for the current fiscal year.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
Further Reading
- Five stocks we like better than Codexis
- What is the Dogs of the Dow Strategy? Overview and Examples
- Should You Invest in Bitcoin? Pros and Cons
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- The Role Economic Reports Play in a Successful Investment Strategy
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.